Leronlimab
CAS No. 674782-26-4
Leronlimab( —— )
Catalog No. M36806 CAS No. 674782-26-4
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody with both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV, non-alcoholic steatohepatitis (NASH), and breast cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 301 | Get Quote |
|
| 5MG | 550 | Get Quote |
|
| 10MG | 882 | Get Quote |
|
| 25MG | 1260 | Get Quote |
|
| 50MG | 1702 | Get Quote |
|
| 100MG | 2232 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLeronlimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLeronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody with both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV, non-alcoholic steatohepatitis (NASH), and breast cancer.
-
DescriptionLeronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.
-
In VitroCell Cytotoxicity Assay Cell Line:MDA-MB-231 cell line Concentration:10 μg/mL Incubation Time:72 hours Result:Increased the cells killing effect induced by doxorubicin.
-
In VivoAnimal Model:Female NCI Athymic nu/nu nude mice with MB-MDA-231 cells expressing Luc2-eGFP injection Dosage:2 mg Administration:Intraperitoneal injection; 2 mg, twice a week Result:Reduced the volume of pulmonary metastases at 8 weeks.
-
Synonyms——
-
PathwayAutophagy
-
TargetCCR
-
RecptorCCR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number674782-26-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jiao X, et al. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 2021 Jan 23;23(1):11.?
molnova catalog
related products
-
Nazartinib
Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor.
-
CCR4 antagonist 3-1
CCR4 antagonist 3-1 is a less active chemokine receptor 4 (CCR4) antagonist that inhibits [125I]TARC (thymus and activation-regulated chemokine) with an IC50 value of 1.7 μM.
-
SB 297006
SB 297006 is an antagonist of C-C chemokine receptor 3 (CCR3; IC50 = 39 nM), which normally is activated by eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES, and MIP-1δ.
Cart
sales@molnova.com